Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 6 of 154 for:    Dermatitis, Atopic, 8

Delgocitinib Cream for the Treatment of Moderate to Severe Atopic Dermatitis During 8 Weeks in Adults, Adolescents, and Children

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03826901
Recruitment Status : Recruiting
First Posted : February 1, 2019
Last Update Posted : April 22, 2019
Sponsor:
Information provided by (Responsible Party):
LEO Pharma

Brief Summary:
This is a multi-center, open-label trial to evaluate safety and pharmacokinetics of topical delgocitinib cream applied to pediatric subjects(2-17 years) and adult subjects (18 years and above) with atopic dermatitis.

Condition or disease Intervention/treatment Phase
Atopic Dermatitis Drug: delgocitinib Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 44 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Open-label, Multi-centre, Single-arm Trial to Evaluate the Safety and Pharmacokinetics (Including MUsT) of Twice Daily Topical Application of Delgocitinib Cream for 8 Weeks in Adults, Adolescents, and Children With Moderate to Severe Atopic Dermatitis
Actual Study Start Date : February 20, 2019
Estimated Primary Completion Date : May 16, 2020
Estimated Study Completion Date : December 4, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eczema

Arm Intervention/treatment
Experimental: Part 1: adults and adolescents (12 years and above)
Delgocitinib cream (dosage: A mg/g).
Drug: delgocitinib
Cream for topical application
Other Name: LEO 124249

Experimental: Part 2: children (2-11 years)
Delgocitinib cream (dosage: B mg/g).
Drug: delgocitinib
Cream for topical application
Other Name: LEO 124249




Primary Outcome Measures :
  1. Adverse events (AEs) [ Time Frame: Week 0 to Week 8 ]
    Number of AEs and number of subjects with AEs


Secondary Outcome Measures :
  1. PK parameter - Cmax [ Time Frame: at Day 8 ]
    Cmax

  2. PK parameter - AUC [ Time Frame: at Day 8 ]
    AUC

  3. PK parameter - tmax [ Time Frame: at Day 8 ]
    tmax



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   2 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion criteria (Part 1: adults and adolescents; 12 years and above)

  • Diagnosis of atopic dermatitis (AD) as defined by the Hanifin and Rajka (1980) criteria for AD
  • Age 12 years and above at baseline
  • AD involvement of 25-50% treatable body surface area (BSA) at screening and at baseline
  • Moderate to severe AD (Validated Investigator Global Assessment scale for Atopic Dermatitis [vIGA-AD] score of at least 3) at screening and at baseline

Key Inclusion criteria (Part 2: children; 2-11 years)

  • Diagnosis of AD as defined by the Hanifin and Rajka (1980) criteria for AD
  • Age 2-11 years at baseline
  • History of AD for at least 3 months (children aged 2-5 years), and at least 12 months (children aged 6-11 years)
  • AD involvement of 30-50% treatable BSA at screening and at baseline
  • Moderate to severe AD (vIGA-AD score of at least 3) at screening and at baseline

Key Exclusion criteria (Part 1 and 2: subjects aged 2 years and above)

  • Active dermatologic conditions that may interfere with the diagnosis of AD
  • Use of tanning beds or phototherapy within 4 weeks prior to baseline
  • Systemic treatment with immunosuppressive/modulating drugs or corticosteroids within 4 weeks prior to baseline or 3 or more bleach baths any week within 4 weeks prior to baseline
  • Treatment with topical corticosteroids (TCS), topical calcineurin inhibitors (TCIs), topical phosphodiesterase-4, or oral antibiotics within 1 week prior to baseline
  • Clinically significant infection (systemic infection or serious skin infection requiring parenteral treatment) within 4 weeks prior to baseline
  • Any disorder, which is not stable, and in the investigator's opinion could affect the safety of the subject, influence the results of the trial or impede the subject's ability to complete the trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03826901


Contacts
Layout table for location contacts
Contact: Clincal Disclosure (+1) 877-557-1168 disclosure@leo-pharma.com

Locations
Layout table for location information
United States, Arizona
LEO Pharma investigational site Recruiting
Phoenix, Arizona, United States, 85006
Principal Investigator: Lindsay Ackerman         
United States, California
LEO Pharma investigational site Recruiting
Fountain Valley, California, United States, 92708
Principal Investigator: Vivian Laquer         
LEO Pharma investigational site Not yet recruiting
Irvine, California, United States, 92697
Principal Investigator: Natasha Mesinkovska         
LEO Pharma investigational site Recruiting
Los Angeles, California, United States, 90027
Principal Investigator: Peck Ong         
United States, Colorado
LEO Pharma investigational site Recruiting
Centennial, Colorado, United States, 80112
Principal Investigator: Isaac Melamed         
United States, Connecticut
LEO Pharma investigational site Recruiting
New Haven, Connecticut, United States, 06519
Principal Investigator: Richard Antaya         
United States, Indiana
LEO Pharma investigational site Recruiting
Indianapolis, Indiana, United States, 46250
Principal Investigator: Scott Fretzin         
United States, Michigan
LEO Pharma investigational site Recruiting
Ypsilanti, Michigan, United States, 48197
Principal Investigator: Jeffrey Leflein         
United States, Oregon
LEO Pharma investigational site Recruiting
Medford, Oregon, United States, 97504
Principal Investigator: Edward Kerwin         
Canada, Alberta
LEO Pharma investigational site Recruiting
Red Deer, Alberta, Canada, 46-37535
Principal Investigator: Isaiah Day         
Canada, Ontario
LEO Pharma investigational site Recruiting
Hamilton, Ontario, Canada, L8S 1G5
Principal Investigator: Jason Ohayon         
Canada, Quebec
LEO Pharma investigational site Not yet recruiting
Montreal, Quebec, Canada, H3T 1C5
Principal Investigator: Danielle Marcoux         
LEO Pharma investigational site Recruiting
Montréal, Quebec, Canada, H2K 4L5
Principal Investigator: Robert Bissonnette         
Sponsors and Collaborators
LEO Pharma
Investigators
Layout table for investigator information
Study Director: Medical Expert LEO Pharma

Layout table for additonal information
Responsible Party: LEO Pharma
ClinicalTrials.gov Identifier: NCT03826901     History of Changes
Other Study ID Numbers: LP0133-1181
First Posted: February 1, 2019    Key Record Dates
Last Update Posted: April 22, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

De-identified IPD can be made available to researchers in a closed environment for a specified period of time.

Data-sharing is subject to approved scientifically sound research proposal and signed data-sharing agreement.

Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Clinical Study Report (CSR)
Time Frame: Data is available to request after approval of the studied indication.
URL: http://www.leo-pharma.com/Home/Research-and-Development/Clinical-trial-disclosure/Access-to-patient-level-data.aspx

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by LEO Pharma:
adults, pediatric
Additional relevant MeSH terms:
Layout table for MeSH terms
Dermatitis, Atopic
Dermatitis
Eczema
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases